Ensign Peak Advisors Inc Sells 25,590 Shares of Edwards Lifesciences Co. (NYSE:EW)

Ensign Peak Advisors Inc decreased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 9.6% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 239,886 shares of the medical research company’s stock after selling 25,590 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Edwards Lifesciences were worth $22,158,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. DSM Capital Partners LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $28,000. Crewe Advisors LLC bought a new position in Edwards Lifesciences in the first quarter valued at about $28,000. First Community Trust NA acquired a new stake in Edwards Lifesciences in the second quarter worth about $29,000. Riverview Trust Co bought a new stake in Edwards Lifesciences during the 1st quarter worth about $34,000. Finally, Pingora Partners LLC acquired a new position in Edwards Lifesciences during the 4th quarter valued at about $38,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,101,530.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. The disclosure for this sale can be found here. Insiders sold a total of 16,250 shares of company stock valued at $1,218,138 over the last three months. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

EW opened at $66.83 on Monday. The business’s 50-day simple moving average is $69.89 and its 200 day simple moving average is $82.80. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The firm has a market capitalization of $40.27 billion, a PE ratio of 28.81, a PEG ratio of 2.85 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. The business had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.66 earnings per share. As a group, sell-side analysts expect that Edwards Lifesciences Co. will post 2.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on EW. StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, July 25th. TD Cowen cut Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their price target for the company from $100.00 to $70.00 in a research note on Thursday, July 25th. Stifel Nicolaus decreased their price objective on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a report on Thursday, July 25th. Robert W. Baird downgraded shares of Edwards Lifesciences from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $102.00 to $70.00 in a research note on Thursday, July 25th. Finally, Barclays reduced their target price on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Sixteen equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $79.82.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.